Editorial Staff

Study: Massachusetts Should Embrace Direct Healthcare Options

/in , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

RevCycle Intelligence: Direct Primary Care Increases Patient-Centered Care Access

Approach to investing in primary care yields lower costs, greater efficiency and increased patient satisfaction

BOSTON – Especially in the COVID era, many are looking to alleviate the increased burden on the healthcare system.  One solution is direct healthcare (DHC), which can provide more patient-centered care at affordable prices and is an effective model to increase access to care for the uninsured, underinsured and those on public programs like Medicaid, according to a new study published by Pioneer Institute.

“This approach to investing in primary care has been shown to reduce costs, emergency room visits, inpatient care and visits to specialists, all while increasing patients’ satisfaction with their care,” said Josh Archambault, co-author with Greg George of “Direct Health Care Agreements: A New Option for Patient-Centered Care That Costs Less and Reduces Provider Burnout.”

Under DHC, patients pay practices a set monthly fee that covers a prearranged universe of services.  It is most common in primary care, but can be used for other types of care such as physical therapy, behavioral and mental health, and dentistry.  There are currently 1,200 direct primary care (DPC) practices in the U.S., at least 16 of which are in Massachusetts.

For primary care, patients begin by choosing their provider, then purchase a complementary insurance plan.  They can usually buy a much less expensive plan with a higher deductible because they have access to so many services through DPC.

DPC agreements commonly include:

  • Unlimited office visits
  • Home visits
  • Same- or next-day appointment availability
  • Longer visit durations
  • Annual physicals
  • Vaccinations
  • Routine lab tests
  • Stitches and splintering or casting of fractured or broken bones
  • Help navigating the rest of the healthcare system
  • 24/7 emergency triage support

Some agreements include access to generic prescription drugs at near wholesale prices.  Many DPC physicians give patients their personal cell phone numbers.

In 2018, nearly 80 percent of DPC subscription fees were between $51 and $99 per month, and costs have been stable over time.  About 60 percent of patients who belong to a DPC practice have an annual household income of $95,000 or less.

One DPC provider shared the story of an uninsured 30-year-old man who pays $648 a year for access to the direct primary care practice.  Since joining the practice the patient has suffered from a serious sinus infection, recurrence of cellulitis with abscesses that required draining, had multiple musculoskeletal injuries due to a car crash, and needed an x-ray for a possible femur fracture.  The only additional cost to the patient for treatment of all these ailments was a $60 x-ray and inexpensive antibiotics.  All other care was provided for under the $648.  If he had sought care at the emergency room for any of the ailments, his bill for one visit would have been two or three times that amount.

There are no deductibles, co-pays or third-party insurance claims.  The transparency and lack of surprise bills address the issue of those who don’t see their doctors because of uncertainty over the cost.

DPC patients have an average of four, 35-minute visits a year with their physician.  Under the typical fee-for-service model, patients have 1.66 visits annually and spend around 15 minutes per visit with their physician.

DHC also results in far less physician burnout. “Status quo” providers currently report spending around a third of their day on administrative tasks, by contrast direct care providers spend much more time with patients because there is no paperwork to fill out for insurers.

DHC could help a number of patient groups.  Access to same- or next-day appointments could be particularly helpful to MassHealth members.  Pre-pandemic, the average wait for a doctor’s appointment in Boston was 50 days, and many providers don’t accept Medicaid.

Older adults on Medicare who often have trouble finding transportation to medical appointments could benefit from the home visits usually included in DPC agreements and from the more personal management of chronic illnesses that comes with longer and more frequent appointments.

A study published in the American Journal of Primary Care found that a small subset of direct health care arrangements studied resulted in a $119.4 million decrease in preventable hospital use in these practices in New York, Florida, Virginia, Arizona and Nevada.  Over 90 percent of the savings – $2,551 per patient – came from Medicare patients.

DHC also offers an innovative option for small businesses.  Superior Packaging and Finishing in Braintree saved $370,000 in a year, or over $4,300 per enrolled employee, when the company switched to offering a DPC plan to its employees.

Archambault urges the Commonwealth to take four steps to embrace DHC:

  1. Division of Insurance guidance should be updated to match 35 other states by clarifying that any form of direct care should not be regulated like insurance. If there was clear support, the Legislature could codify this standard.
  2. The Group Insurance Commission should embrace direct health care arrangements for public employees and offer it as a lower-cost option.
  3. MassHealth should explore DHC arrangements, especially for some of the sickest patients on the program.
  4. The Legislature could consider requiring that insurance companies offer at least one product to consumers that wraps around DHC arrangements, especially DPC. This reform would introduce a new, less-expensive option for consumers, as the product would have a higher deductible than most plans currently offered in Massachusetts.

About the Authors

Josh Archambault is a Senior Fellow at Pioneer Institute. Prior to joining Pioneer, Josh was selected as a Health Policy Fellow at the Heritage Foundation in Washington, D.C. In the past, Josh served as a Legislative Director in the Massachu­setts State Senate and as Senior Legislative Aide in the Governor’s Office of Legislative Affairs. His work has appeared or been cited in outlets such as USA Today, Wall Street Journal, The New York Times, Fox News, NPR, Boston Herald and The Boston Globe. He is the editor and coauthor of The Great Experiment: The States, The Feds, and Your Healthcare. Josh holds a Master’s in Public Policy from Harvard University’s Kennedy School and a BA in Political Studies and Economics from Gordon College.

Greg George is the health policy and state affairs advisor for the Mackinac Center for Public Policy.  Prior to joining Mackinac, Greg served as a senior research fellow at the Foundation for Government Accountability. He has also been a policy advisor for the Michigan House of Representatives and legislative director for the Michigan Speaker Pro Tempore. He holds a Bachelor of Science in Finance from Hillsdale College and a Master of Business Administration from Western Michigan University.

About Pioneer

Pioneer’s mission is to develop and communicate dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Pioneer’s vision of success is a state and nation where our people can prosper and our society thrive because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and where our government is limited, accountable and transparent.

Pioneer values an America where our citizenry is well-educated and willing to test our beliefs based on facts and the free exchange of ideas, and committed to liberty, personal responsibility, and free enterprise.

Get Updates On Our Healthcare Research and Events!

Related Posts

How did COVID impact Massachusetts’ long-term care facilities?

Pioneer Institute has filed a Public Records Act request related to COVID's impact on Massachusetts’ long-term care facilities because the Institute believes this is a matter of obvious importance, both on principle (the public has a right to know the facts), and for purposes of evaluating – and where possible improving – public policy. 

Massachusetts Telehealth Report Card: Are We Embracing Disruption for Better Quality of Care?

Hubwonk host Joe Selvaggi talks with Pioneer Senior Fellow in Healthcare Josh Archambault about his newest research paper, produced with the Cicero Institute and the Reason Foundation, on states' success in implementing telehealth to improve healthcare outcomes. They discuss how Massachusetts has used remote medicine to better reach patients and serve their needs.

Am I Contagious? Divining Covid’s Community Conundrum

Hubwonk host Joe Selvaggi talks with Alva10 CEO and precision medicine expert Hannah Mamuszka about which tests are best for determining who is contagious and the implications for the CDC’s new isolation recommendations.

Face Masks Lifted: Scientists Weigh In With Comprehensive Efficacy Studies

Hubwonk host Joe Selvaggi talks with Harvard Medical School professor, Dr. Jonathan Darrow, about the observations of his recent paper, Evidence for Community Cloth Face Masking to Limit the Spread of SARS-CoV-2: A Critical Review, in which he examines the range, quality, and scientific observations of mask wearing efficacy studies.

Building Healthcare Bigger: New Bill Is Good Medicine or Ill-Designed Cost Shift

This week on Hubwonk, host Joe Selvaggi talks with Josh Archambault, Pioneer Institute’s Senior Fellow in Healthcare, about the healthcare provisions in the pending Build Back Better Act and their likely impact on the coverage and cost to Americans in the wake of Covid-19.

The Promise and Challenges of Rare Cancer Treatments

Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum. 

COVID’s Unintended Victims: Traditional Diseases Overlooked at the Public’s Peril

This week on Hubwonk, host Joe Selvaggi talks with Pioneer Institute’s Visiting Fellow in Life Sciences, Dr. Bill Smith, about his newest research paper, “An “Impending Tsunami” in Mortality from Traditional Diseases,” which sounds the alarm that the public health community’s focus on COVID-19 has caused many to avoid seeking medical attention for other illnesses. As a result, more Americans are dying from fear of COVID than from the disease itself.

Vaccine Development Renaissance: Pandemic Brings Niche Industry into Mainstream

This week on Hubwonk, host Joe Selvaggi talks with virologist, Dr. Peter Kolchinsky, about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease.

Shifting COVID-19 Goalposts: Moving from Zero Infections to Zero Deaths

This week on Hubwonk, host Joe Selvaggi talks with surgeon and author Dr. Marty Makary about the power and durability of vaccines, natural immunity and clinical therapies, that are overshadowed by the public health community's continued target of zero COVID-19 infections.
A Woman Helping a Disabled Man in a Wheelchair

An Act advancing health care research and decision-making centered on patients and people with disabilities

On November 9th, 2021, William Smith, Pioneer Institute Visiting Fellow in Life Sciences, submitted the following testimony to the Massachusetts Legislature in support of House Bill 201, which addresses a number of flaws and infirmities in the Quality Adjusted Life Years (QALYs) methodology that is utilized by a number of foreign nations in evaluating the value of medicines.

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Untangling Variants & Outbreaks: Can Vaccines & Natural Immunity Outrun Delta?

Hubwonk host Joe Selvaggi talks with author, surgeon, and public health expert Dr. Marty Makary about the COVID-19 Delta Variant, the durability of natural and vaccinated immunity, the benefits of booster shots, and the health risks for children as we move into the fall.

Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag

Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.

Pioneer Institute Statement on the Commonwealth’s Discontinuance of the COVID-19 Weekly Public Health Report

Useful information about COVID cases or deaths at individual homes has become less available at a time when cases are increasing again, even among vaccinated residents. Pioneer urges Massachusetts to immediately reinstate the so-called Weekly Report, which contains cases and deaths inside individual nursing homes.

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute's Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.